Stefano Scalera

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Journal: Experimental and molecular pathology

Published: May 28, 2026

Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC.

Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC.

Journal: Molecular oncology

Published: May 26, 2026

Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

Journal: medRxiv : the preprint server for health sciences

Published: May 25, 2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 17, 2026

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 06, 2026

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

Journal: Experimental and molecular pathology

Published: January 26, 2026

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 17, 2025

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.

Journal: International journal of molecular sciences

Published: December 04, 2025

Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors.

Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors.

Journal: International journal of molecular sciences

Published: December 02, 2025

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 21, 2025

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer.

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer.

Journal: Molecular oncology

Published: September 24, 2025

PROTAC-based protein degradation: a window of opportunity for melanoma therapy.

PROTAC-based protein degradation: a window of opportunity for melanoma therapy.

Journal: Journal of biomedical science

Published: September 18, 2025

Showing 1-12 of 47

Last Updated: 09/26/2026